Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients

NCT03473574 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

128

Enrollment

OTHER

Sponsor class

Conditions

Cholangiocarcinoma
Gall Bladder Carcinoma
Cholangiocarcinoma Non-resectable
Gallbladder Carcinoma Non-Resectable

Interventions

BIOLOGICAL: Durvalumab
DRUG: Gemcitabine
DRUG: Cisplatin
BIOLOGICAL: Tremelimumab

Sponsor

AIO-Studien-gGmbH

Collaborators

[object Object]